Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive IgM-enriched immunoglobulin therapy with personalized vs standard dosing in septic shock
2024-518096-57-00Phase 3Authorised
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Nov 2024
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Pentaglobin in septic shock (2 arms), sponsored by Azienda Ospedaliera Universitaria Policlinico. Primary endpoint: All-cause mortality at day 28. Planned start Nov 2024; status: authorised.
02
Drugs
Pentaglobin
03
Conditions
septic shock
Beyond the preview
Go deeper on 2024-518096-57-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518096-57-00.